Syracuse – – September 28, 2026 -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, have launched a proof of concept for FuseRx, a clinical workflow platform for radiation oncology, at AMP's Center of Advanced Radiation Excellence in Syracuse.
Prostate cancer volume drives the test case
The American Cancer Society projects about 333,800 new U.S. prostate cancer cases in 2026, making it the most common cancer in American men after skin cancer. Roughly a third of men with localized disease receive radiation as primary treatment, a pathway that typically starts with a urologist diagnosis before crossing into separate oncology systems.
FuseRx integrates ACRO clinical pathways at the point of care
The Syracuse pilot begins with the physician consult workflow, embedding the applicable American College of Radiation Oncology (ACRO) pathway directly into the consult note and treatment intent. The rollout will extend over coming months to cover physicists, dosimetrists, therapists and nurses on a single plan. FuseRx operates alongside a practice's existing EMR and oncology information system. Fuse and ACRO first announced their pathway-integration agreement in March 2025.
Program is led by a newly named ASTRO Fellow
Steven E. Finkelstein, MD, DABR, FACRO, FASTRO, National Director of the Center of Advanced Radiation Excellence and Director of Radiation Oncology Research for AMP and U.S. Urology Partners, is leading the proof of concept. Finkelstein was named a Fellow of the American Society for Radiation Oncology in July 2026, sits on ACRO's Board of Chancellors, and chairs the board of ACRO's Luther Brady Foundation. In August, his team treated the first U.S. patient under Pluvicto's newly approved indication for metastatic hormone-sensitive prostate cancer.
"A urology practice sees prostate cancer from the first PSA to the last follow-up. When radiation is the right answer, the patient shouldn't wait while paperwork moves between systems," Finkelstein said.
Independent urology groups are internalizing radiation oncology
James Bauler, CEO of Fuse Oncology, said independent urology practices that have brought radiation oncology in-house offer a testing ground for consolidated workflow software because diagnosis and treatment already sit under one roof. AMP is one such group operating under the U.S. Urology Partners umbrella.